MedTrace Logo

Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme.

NCT01301430 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2022-11-21

No results posted yet for this study

Summary

Investigation on safety, tolerability and efficacy of H-1 parvovirus (H-1PV) in subjects suffering from glioblastoma multiforme.

Conditions

Interventions

DRUG

H-1PV

H-1PV administered at three increasing doses either intratumorally or intravenously and then 10 days after the first administration intracerebrally (into the walls of tumor resection cavity).

Sponsors & Collaborators

  • Oryx GmbH & Co. KG

    lead INDUSTRY

Principal Investigators

  • Andreas Unterberg, Prof. Dr. · Department of Neurosurgery, University Hospital Heidelberg

  • Bernard Huber, Dr. · Oryx GmbH & Co. KG

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2015-05-31
Completion
2015-05-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01301430 on ClinicalTrials.gov